| electron carrier | <chemistry> A protein which can either accept or donate electrons in oxidation-reduction reactions. (19 Jan 1998) |
|---|---|
| translocation carrier | A person with balanced translocation. (05 Mar 2000) |
| ubiquitin carrier protein kinase | <enzyme> A 300 kD kinase consisting of 3 subunits of mws 70, 105 and 120; requires magnesium but inhibited by high concentration; from hela cells Registry number: EC 2.7.10.- (26 Jun 1999) |
| lactose carrier protein | <protein> The best known example is the product of the lacY gene, coded for in the lactose operon and responsible for the uptake of lactose by E. Coli. (18 Nov 1997) |
| 3-oxoacyl-(acyl-carrier-protein) synthase | <enzyme> An enzyme of long-chain fatty acid synthesis, that adds a two-carbon unit from malonyl-(acyl carrier protein) to another molecule of fatty acyl-(acyl carrier protein), giving a beta-ketoacyl-(acyl carrier protein) with the release of carbon dioxide. Chemical name: Acyl-(acyl carrier protein):malonyl-(acyl-carrier-protein) C-acyltransferase (decarboxylating) Registry number: EC 2.3.1.41 (12 Dec 1998) |
| latent carrier | A person, typically a prospective parent, bearing the appropriate genotype of a trait (homozygous for recessive, homozygous or heterozygous for dominant, hemizygous or homozygous for X-linked) that manifests the trait only under certain conditions, e.g., age, an environmental insult, etc. (05 Mar 2000) |
| long-chain-fatty-acid-(acyl-carrier-protein) ligase | <enzyme> Fatty acid, acyl-carrier-protein-sh and ATP gives acyl-(acyl-carrier-protein), AMP and ppi Registry number: EC 6.2.1.20 Synonym: fatty acid-acyl carrier protein ligase (AMP), acyl-(acyl-carrier-protein)synthetase, aacp synthetase, fatty acyl-acyl carrier protein synthase, vibrio harveyi, acyl-(acyl-carrier-protein) synthetase, acyl-acp synthetase (26 Jun 1999) |
| abnormalities, drug-induced | Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. (12 Dec 1998) |
| activity, drug | A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa). (12 Dec 1998) |
| addictive drug | Any drug that creates a certain degree of euphoria and has a strong potential for addiction. (05 Mar 2000) |
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
| akathisia, drug-induced | Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation). (12 Dec 1998) |
| antineoplastic drug | A drug that stops or slows the maturation and spread of tumour cells (benign or malignant). (09 Oct 1997) |
| maintenance drug therapy | In chemotherapy, systematic dosage at a level that maintains protection against exacerbation. (05 Mar 2000) |
| rational drug design | <pharmacology> Modeling the molecular structure of the target of a drug, for example, an antigen, and then designing a drug that will attack it. (17 Dec 1997) |